Additional Glucose Lowering and Anti-Inflammatory Effects by Acarbose and Alcohol in Subjects With Impaired Glucose Tolerance or Mild Type 2 Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2007 by Taichung Veterans General Hospital. Recruitment status was Recruiting

First Received on January 1, 2007. Last Updated on January 3, 2007 History of Changes

Sponsor:	Taichung Veterans General Hospital
Collaborator:	Tri-Service General Hospital
Information provided by:	Taichung Veterans General Hospital
ClinicalTrials.gov Identifier:	NCT00417950

Purpose

To understand if acarbose, an alpha-glucosidase inhibitor usually for treating diabetes, will further lower post meal glucose and inflammatory state when taking together with moderate amount of alcohol during meal tolerance test in subjects with impaired glucose tolerance or mild diabetes.

Condition	Intervention
Diabetes Mellitus Impaired Glucose Tolerance	Drug: Acarbose

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

Drug Information available for: Acarbose

U.S. FDA Resources

Further study details as provided by Taichung Veterans General Hospital:

Primary Outcome Measures:

Postprandial hyperglycemia

Secondary Outcome Measures:

Postprandial inflammatory responses
Postprandial oxidative stress

Estimated Enrollment:	30
Study Start Date:	January 2007

Eligibility

Ages Eligible for Study:	25 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects with mild diabetes without prior medications or impaired glucose tolerance

Exclusion Criteria:

Pregnancy
Recent major cardiac, renal and hepatic disease
Intolerance to alcohol
Allergy to acarbose treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00417950

Contacts

Contact: I Te Lee, MD, MS

886-4-23592525 ext 3065

itlee@vghtc.gov.tw

Locations

Taiwan
Taichung Veterans General Hospital	Recruiting
Taichung, Taiwan
Contact: Wayne H Sheu, MD, PhD 886-4-23592525 ext 3068 whhsheu@vghtc.gov.tw
Principal Investigator: Wayne H Sheu, MD, PhD
Sub-Investigator: I Te Lee, MD, MS

Sponsors and Collaborators

Taichung Veterans General Hospital

Tri-Service General Hospital

Investigators

Principal Investigator:

Wayne H Sheu, MD, PhD

Taichung Veterans General Hospital

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00417950 History of Changes
Other Study ID Numbers:	950801/C06138
Study First Received:	January 1, 2007
Last Updated:	January 3, 2007
Health Authority:	Taiwan: Department of Health

Keywords provided by Taichung Veterans General Hospital:

diabetes
acarbose
alcohol

inflammation
oxidative stress
Mild diabetes mellitus

Additional relevant MeSH terms:

Diabetes Mellitus
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hyperglycemia

Acarbose
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 09, 2012